Andersen Sarah, Kennedy Glen, Banks Merrilyn
Department of Nutrition and Dietetics, Royal Brisbane and Women's Hospital, Herston, QLD 4029, Australia.
Clinical Haematology, Royal Brisbane and Women's Hospital, Herston, QLD 4029, Australia; University of Queensland, St Lucia, Brisbane, 4072, Australia.
Clin Nutr ESPEN. 2015 Jun;10(3):e102-e106. doi: 10.1016/j.clnesp.2015.04.001. Epub 2015 May 21.
Nutritional support during allogeneic haematopoietic progenitor cell transplantation (HPCT) is imperative to prevent malnutrition and poorer patient outcomes. However, there is little literature on the most efficacious approach, leading to wide variation in the use of enteral (EN) and parenteral (PN) feeding across HPCT units. This study aimed to determine the tolerability and efficacy of EN versus PN in patients undertaking allogeneic HPCT.
A randomised controlled trial was conducted from September 2011 to January 2013. Patients were randomized to receive either EN (nasogastric) or PN if nutrition support was required, however those with severe gastro-intestinal toxicity, including severe mucositis, were excluded from randomisation. If patients did not tolerate the type of feeding given they were swapped to the alternate route.
Nine patients were able to be randomized between EN (n = 5) and PN (n = 4). The patients randomized to EN all required changing to PN due to gastro-intestinal intolerance (p≤0.01). None of the patients receiving PN required changing to EN.
This study demonstrates that due to the significant gastrointestinal toxicity, EN was not feasible to commence when oral intake became inadequate. This study was registered with the Australian New Zealand Clinical Trials Registry (ANZCTR), Trial Number ACTRN12611001084976.
异基因造血祖细胞移植(HPCT)期间的营养支持对于预防营养不良和改善患者预后至关重要。然而,关于最有效方法的文献很少,导致各HPCT单位在肠内营养(EN)和肠外营养(PN)的使用上存在很大差异。本研究旨在确定接受异基因HPCT的患者中EN与PN的耐受性和疗效。
2011年9月至2013年1月进行了一项随机对照试验。如果需要营养支持,患者被随机分配接受EN(鼻胃管)或PN,然而,患有严重胃肠道毒性(包括严重黏膜炎)的患者被排除在随机分组之外。如果患者不耐受所给予的喂养方式,则改为另一种途径。
9名患者能够在EN组(n = 5)和PN组(n = 4)之间进行随机分组。随机分配到EN组的所有患者由于胃肠道不耐受都需要改为PN(p≤0.01)。接受PN的患者中没有人需要改为EN。
本研究表明,由于严重的胃肠道毒性,当口服摄入量不足时开始EN是不可行的。本研究已在澳大利亚新西兰临床试验注册中心(ANZCTR)注册,试验编号为ACTRN12611001084976。